Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA: First Adapted COVID-19 Vaccines Expected In September

Data Still Awaited On Valneva Vaccine & Molnupiravir

Executive Summary

As work continues on vaccines adapted to tackle variants of SARS-CoV-2, the EU regulator says the decision-making on such products should take place at a global level.

You may also be interested in...



Coronavirus Notebook: Adapted Comirnaty Vaccine Under EU Review, Sanofi & GSK Laud Next-Gen Booster

Valneva expects its vaccine candidate to be approved this month. Meanwhile, the core functions of the UK’s Vaccine Taskforce are to be transferred to the UK Health Security Agency and the Office for Life Sciences.

Coronavirus Notebook: Moderna Postpones EU Spikevax Supplies, Industry Insists TRIPS Waiver Is Redundant

The medical NGO, MSF, has urged countries not to adopt the latest draft of the proposed waiver, saying it would impair efforts to boost access to COVID-19 products around the world. The WHO has been looking at the benefits of hybrid immunity – and how far it might be waning.

Coronavirus Notebook: New EU Body To Advise On Future Pandemic Actions, Valneva Awaits EMA Verdict On Vaccine Candidate

French health tech firm NOVA has produced a model for assessing the impact of non-pharmaceutical COVID-19 interventions on clinical trials of respiratory tract drugs, and Moderna’s Spikevax has been OKd for younger children in Great Britain.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel